Skip to Content

Ascensia study shows reduction in blood glucose readings

Ascensia study shows reduction in blood glucose readings

BASEL, Switzerland – People who use Ascensia Diabetes Care’s connected CONTOUR BGM systems (BGMS) and CONTOUR DIABETES App (CDA) for at least six months can see a reduced frequency of hypoglycemic and hyperglycemic blood glucose readings, according to a new study from the company. “We’re pleased to see results from the study showcasing that our CDA system is helping people with diabetes to manage their condition,” said Frank Held, head of BGM marketing and strategy. “While many diabetes apps support people with diabetes in managing their condition, they don’t all provide alerts or guidance for hypoglycemic or hyperglycemic events, like the CONTOUR DIABETES App does. Failure to properly address these events can result in serious health complications, so it is crucial that monitoring systems and connected apps facilitate the detection of high and low blood glucose levels.” The study assessed data from 7,047 CDA system users in Australia. After six months, the estimated frequency of BGRs in high and very high ranges in people using the CDA system fell by more than 6.5-times and 5.6-times, respectively, compared to baseline. This decrease was more prominent among users who reported the use of oral antidiabetic medications, at 7.37-times less than baseline. The decrease of BGRs in the low range was modest at 1.2-times in the entire assessed population, and at 1.38-times in CDA system users who were treated with insulin and are more prone to hypoglycemic events. These data suggest improved glycemic control when using the CDA system for at least six months and, more generally, a key benefit in using connected BGMS, including apps, to support the management of diabetes. 

Comments

To comment on this post, please log in to your account or set up an account now.